European Association for the Study of Diabetes (EASD) Annual Meeting 2026

Milan, Italy 28 September 2026 - 02 October 2026

ACHIEVE-4: Oral GLP-1 RA pill safe for the heart

02 Nov 2026 by

Orforglipron has demonstrated cardiovascular (CV) safety in adults with type 2 diabetes (T2D) and obesity or overweight who are at high cardio-renal risk, as shown in the phase III ACHIEVE-4 study.

02 Nov 2026

CGM initiation reduces hospitalizations for acute diabetes events

26 Oct 2026 by

In an observational study, the rates of hospitalizations for acute diabetes events (ADEs) decreased following the initiation of the FreeStyle Libre (FSL) continuous glucose monitoring (CGM) system in adults with type 2 diabetes (T2D).

26 Oct 2026

Retatrutide poised to be the next weight-loss option for T2D with obesity

24 Oct 2026 by

In the phase III TRIUMP-2 trial, retatrutide improves glycaemic control and reduces body weight in adults with type 2 diabetes (T2D) who are overweight or have obesity, potentially expanding weight-loss options for this population.

24 Oct 2026

GLP-1 RA/SGLT-2i combo provides enhanced protection against dementia in T2D patients

22 Oct 2026 by

Type 2 diabetes (T2D) patients receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) concomitantly appear to be at lower risk of dementia compared with those receiving a GLP-1 RA or SGLT-2i monotherapy, according to a study.

22 Oct 2026

Switch to oral semaglutide benefits patients with overweight, obesity

22 Oct 2026 by

Individuals with overweight or obesity lost a significant amount of weight 3 months after switching from an injectable formulation of semaglutide or tirzepatide to oral semaglutide, findings from the real-world OCTANE trial have shown. The switch was also associated with high treatment adherence and satisfaction.

22 Oct 2026

TG103 noninferior to dulaglutide for HbA1c reduction in Chinese adults with T2D

20 Oct 2026 by

Once-weekly TG103, a novel long-acting GLP-1*/Fc fusion protein, demonstrates noninferiority to dulaglutide in reducing HbA_1c in Chinese patients with type 2 diabetes (T2D) inadequately controlled on metformin, according to a phase III trial presented at EASD 2026.

20 Oct 2026

Triple therapy with empagliflozin, metformin, evogliptin works well in T2D

17 Oct 2026 by

In the treatment of patients with uncontrolled type 2 diabetes (T2D), adding empagliflozin to the combination of metformin plus evogliptin improves glycaemic control and other metabolic outcomes, as shown in a phase III study conducted in South Korea.

17 Oct 2026

Novel dual GLP-1/GIP receptor agonist confers weight-loss benefit with low GI events

16 Oct 2026 by

Subcutaneous injections of olatorepatide, an investigational dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, are associated with up to a 19-percent decrease in body weight and favourable gastrointestinal (GI) tolerability in Chinese adults with overweight or obesity, as shown in the phase III LIGHTEN study.

16 Oct 2026

Survodutide reduces weight in adults with obesity, T2D

15 Oct 2026 by

Treatment with the investigational glucagon/GLP-1 receptor dual agonist (RA) survodutide results in significant weight reductions in adults with obesity and type 2 diabetes (T2D), as shown in the SYNCHRONIZE-2 study.

15 Oct 2026